+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.

Age: 55Years - 90YearsAll GendersPhase 3
162 locations
R

Actively Recruiting

This research aims to evaluate the clinical effectiveness, safety, and tolerability of XEN1101 when used alongside other antiseizure medications in adults with focal-onset seizures. It is a Phase 3, randomized, double-blind, placebo-controlled study involving approximately 360 participants. The study focuses on how XEN1101 affects seizure frequency compared to placebo while monitoring any side effects or safety concerns. Participants will be randomly assigned to one of three groups XEN1101 25 mg, XEN1101 15 mg, or placebo, taken once daily with an evening meal. The study includes a baseline period of up to 9.5 weeks to record seizure frequency, followed by 12 weeks of blinded treatment. After this, those who complete the treatment phase may join an open-label extension study for continued XEN1101 treatment, while others will enter an 8-week post-treatment follow-up period. During the study, participants will keep accurate seizure diaries and attend regular visits for assessments including seizure monitoring, safety checks, and tolerability evaluations. Researchers will measure the median percent change in focal seizure frequency from baseline through the 12-week treatment, along with other outcomes such as the proportion of participants experiencing significant seizure reduction and patient-reported global impressions. Safety is monitored from screening through 56 days after the final dose to ensure participant well-being throughout the trial.

Age: 18Years +All GendersPhase 3
103 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT compared to a placebo in treating psychosis linked to Alzheimers Disease. This Phase 3 outpatient study lasts 38 weeks and aims to prevent relapse of psychosis symptoms in affected adults aged 55 to 90. The trial also looks at how long participants stay on treatment without relapse or stopping for any reason, along with monitoring safety and tolerability. Participants are randomly assigned to receive either KarXT capsules in varying doses or placebo capsules. The treatment is administered three times a day during the study period. This double-blind trial ensures neither participants nor researchers know which treatment is given. The study is conducted at multiple centers and includes a placebo control to compare outcomes. Throughout the 38 weeks, participants will attend regular visits for assessments including cognitive tests like the Mini-Mental State Examination, evaluations of psychosis severity, caregiver-reported measures, and safety monitoring such as laboratory tests, vital signs, and adverse event tracking. Researchers will measure the time to relapse and treatment discontinuation, along with side effects and other health indicators. The study is sponsored by Karuna Therapeutics, a Bristol Myers Squibb company.

Age: 55Years - 90YearsAll GendersPhase 3
129 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.

Age: 55Years - 90YearsAll GendersPhase 3
296 locations
L

Actively Recruiting

Researchers are investigating the long-term safety and effectiveness of a combined drug treatment using xanomeline tartratetrospium chloride in an immediate release capsule KarXT and xanomeline enteric capsules KarX-EC for people with agitation linked to Alzheimers Disease. This study is an open-label extension of earlier studies CN012-0023 and CN012-0024. It aims to understand how well these treatments work over time and monitor any side effects. Participants who completed the previous studies will receive specified doses of KarXT and KarX-EC according to a set schedule. This phase 3 study does not include a comparison group and all participants receive the combined treatment. The treatment period lasts approximately 30 weeks, during which the effects and safety of these medications will be observed. During the study, participants will be closely monitored for any adverse events, changes in cognitive function, movement disorders, vital signs, and other health measures. Assessments include scales like the Mini-Mental State Examination MMSE, Abnormal Involuntary Movement Scale AIMS, and others related to agitation and side effects. Safety checks such as lab tests, ECGs, and questionnaires will be regularly conducted. The total study duration for participants is about 30 weeks, with follow-up to evaluate overall treatment tolerability and impact.

Age: 55Years - 90YearsAll GendersPhase 3
252 locations
E

Actively Recruiting

Researchers are evaluating XEN1101 as an additional treatment for people with primary generalized tonic-clonic seizures PGTCS in this Phase 3, multicenter, randomized, double-blind, placebo-controlled trial. The study aims to assess the clinical efficacy, safety, and tolerability of XEN1101 in subjects diagnosed with generalized epilepsy who are currently taking 1 to 3 anti-seizure medications ASMs. Participants must have probable or possible PGTCS and meet specific inclusion criteria. Participants aged 12 years and older will be randomly assigned to receive either XEN1101 or a placebo. Those 18 years and older will receive 25 mg of XEN1101 or placebo daily, while those between 12 and under 18 years may receive 15 mg, 25 mg, or placebo once daily with an evening meal. The study includes a baseline period lasting up to 9.5 weeks to monitor seizure frequency, followed by a 12-week double-blind treatment period. After completing this phase, participants can enter an open-label extension study to continue XEN1101 treatment or join an 8-week post-treatment follow-up. Throughout the study, participants will keep accurate seizure diaries and undergo assessments to measure the median percent change in monthly PGTCS frequency. The study will also monitor safety and tolerability during treatment. Those who do not continue into the extension phase will have follow-up visits for 8 weeks after treatment ends. Overall, the trial involves multiple visits and careful monitoring to evaluate the impact of XEN1101 as adjunctive therapy over several months.

Age: 12Years +All GendersPhase 3
141 locations
L

Actively Recruiting

Researchers are conducting a Phase 3 global, multicenter, 52-week open-label extension study to assess the long-term safety and tolerability of KarXT in people with psychosis associated with Alzheimers Disease. This study includes participants who have completed prior related studies, allowing continued evaluation of this treatment over an extended period. Participants receive KarXT capsules in various doses ranging from 202 mg to 66.76.67 mg three times daily. This extension study follows completion of earlier trials and continues treatment for up to 52 weeks to monitor long-term effects and safety. During the study, participants are monitored for treatment-emergent adverse events from the initial dose through 14 days after the last dose, totaling up to 54 weeks. Researchers track serious adverse events and withdrawals due to adverse events. The involvement lasts approximately one year, focusing on safety and tolerability assessments.

Age: 55Years - 90YearsAll GendersPhase 3
432 locations